Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections

Pediatric Infectious Disease Journal

Volumn 24, Issue 2, 2005, Pages 167-174

  Wiley, Joseph M ^a   Seibel, Nita L ^b   Walsh, Thomas J ^c  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Abelcet; Amphotericin B; Aspergillosis; Candidiasis; Fungal infections; Hematopoietic stem cell transplantation; Mycoses; Organ transplantation

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; CYCLOSPORIN; FLUCONAZOLE; FOSCARNET; GENTAMICIN; TACROLIMUS; TOBRAMYCIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; INFANT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PEDIATRICS; PRIORITY JOURNAL; RANK SUM TEST; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY DISEASES; MALE; MYCOSES; ORGAN TRANSPLANTATION; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 13844298286     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000153183.51258.b8     Document Type: Review

References (16)

1. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
2. Groll AH, Müller FM, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Pädiatr. 1998;210:264-273.
3. Gladdy RA, Richardson SE, Davies HD, Superina RA. Candida infection in pediatric liver transplant recipients. Liver Transplant Sur. 1999;5:16-24.
4. Ringden O, Andstrom EE, Remberger M, Dahllof G, Svahn BM, Tollemar J. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant. 1997;1:124-129.
5. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
6. Abelcet [package insert]. Piscataway, NJ: Enzon Pharmaceuticals, Inc; 2002.
7. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.
8. Ascioglu S, Rex JH, DePauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
9. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr infect Dis J. 1999;18:702-708.
10. Herbrecht R, Auvrignon A, Andrès A, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis. 2001;20:77-82.
11. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-248.
12. Walsh TJ, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
13. Franklin JA, McCormack J, Flynn P. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J. 2003;2:747-749.
14. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-693.
15. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402-1407.
16. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37:415-425.